- Oral presentation
- Open Access
Effect of purified omega-3 fatty acids on reducing left ventricular remodeling after acute myocardial infarction (OMEGA-REMODEL study): a double-blind randomized clinical trial)
© Heydari et al; licensee BioMed Central Ltd. 2015
- Published: 3 February 2015
- Acute Myocardial Infarction
- Infarct Size
- Left Ventricular Remodel
- Post Myocardial Infarction
- PUFA Supplementation
Acute myocardial infarction (MI) remains a leading cause of patient death and morbidity. Prognosis following MI has been shown to be strongly associated with small changes in left ventricular remodeling. Omega-3 fatty acid (PUFAs) supplementation may have a number of beneficial pleiotropic effects, including enhancement of myocardial relaxation1 and reduction of vascular tone.2 One prospective, randomized trial demonstrated significant survival benefit for PUFAs following acute MI.3 However, the mechanism and potential myocardial changes during the convalescent phase post MI from PUFAs have not been well described.
The OMEGA-REMODEL study was a randomized, double-blinded, placebo controlled trial of PUFA supplementation post acute MI. A total of 358 patients were randomized to study therapy with PUFAs (n=180) or matching placebo (n=178) and underwent baseline assessment by CMR 4-28 days following MI, with follow-up after 6 months of randomized therapy. The primary endpoint was changes in left ventricular end-systolic volume indexed to body surface area (LVESVI). Secondary outcomes included a) change in total infarct size, b) expansion of MECVF within noninfarcted myocardium, and c) changes in systemic biomarkers.
The results of this study demonstrated a significant reduction in LVESVI and MECVF for patients treated with high-dose PUFAs as compared to placebo. Further assessment of systemic biomarkers demonstrated a substantial reduction in biomarkers of inflammation, and fibrosis for the PUFAs treated arm. These findings represent the first description of the effect of PUFAs on myocardial tissue phenotypes during the convalescent phase post MI and may suggest potentially important pathophysiological pathways for their pleiotropic effects.
National Institutes of Health Heart, Lung and Blood Institute (NHLBI).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.